Cereno Scientific receives granted patent for CS1 expanding protection in Australia
Cereno Scientific (XSAT: CRNO B) today announced that intellectual property rights (IPR) for drug candidate CS1’s second patent family has been granted in Australia. This is a result of Cereno’s continuous work in securing IPR for its assets to strengthen the commercial positioning. A Phase II study evaluating CS1 for the treatment of pulmonary arterial hypertension (PAH) is planned to start in September 2021.“We are pleased to strengthen the protection around our drug candidate CS1. The addition of also covering Australia for CS1’s second patent family, together with previously granted key